Navigation Links
BCA Represents Independent Blood Centers at Phacilitate Cell & Gene Therapy Forum
Date:1/21/2013

West Warwick, RI (PRWEB) January 21, 2013

Blood Centers of America, Inc. (BCA) announced today it will play a leadership role in representing North American independent blood centers at this year's Phacilitate Cell & Gene Therapy Forum to be held January 28-30, 2013 in Washington, D.C.

BCA will be hosting one-on-one meetings with senior executives of leading cell therapy and cell-based immunotherapy companies, participating in sessions and high-profile networking events, and showcasing BCA member capabilities in the event's 3-day tradeshow.

"Participating in what is often described as one of the leading cell therapy industry conferences of the year is a great way to launch our 2013 initiative to raise the profile of BCA in the cell therapy industry and engage in one-on-one discussions about what BCA has to offer companies in the cell therapy sector," stated BCA's newly appointed CEO, Bill Block.

"BCA is a network of centers geographically dispersed throughout North America with considerable experience in collecting, processing and distributing regulatory-compliant, clinical-grade biologial materials", continued Block. "We are keen to engage cell therapy leadership in a discussion about how we can leverage BCA member infastructure and capabilities in the development and processing of cell therapy products and their safe and cost-effective delivery to patients."

About BCA

BCA is a member-owned organization comprised of 37 independent blood centers geographically dispersed throughout the North America, providing more than 46% of the U.S. blood supply. Along with their core business of providing a substantial portion of U.S. blood supply, BCA members provide a myriad of other services in cell therapies, blood management, therapeutic apheresis, tissue and cord blood banking, etc.

BCA provides thousands of units of biological materials annually to life science researchers, clinicians, therapeutic companies, or companies doing medical device, diagnostic or therapeutic development work.

BCA assists cell therapy companies with securing reliable and compliant sources for the cells used in their therapeutic products and/or pre-clinical research. Where a client need exceeds the capacity of a single center, BCA can assist with putting in place a multi-center supply agreement around cell collections, processing, storage or other handling.

In 2012, BCA generated over $6 million in custom products and services to cell therapy companies including patient-donor collections for autologous cell therapies in clinical trial and commercial distribution.

For more information about how BCA and its services, see http://www.bca.coop.

About the Cell & Gene Therapy Forum

Phacilitate's 9th Annual Cell & Gene Therapy Forum is firmly established as the world’s leading strategy and partnering event for senior decision makers from the global cell therapy, gene therapy and tissue engineered product sectors.

The Cell & Gene Therapy Forum is held along side the Vaccine Forum and the Protein Therapeutics Forum. For more information, see http://www.cgt-forum.com.

Read the full story at http://www.prweb.com/releases/2013/1/prweb10341060.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Butamax Early Adopters Group surpasses capacity targets with addition of Big River; Membership represents 11 production facilities and nearly 900 million gallons of ethanol capacity
2. Independent Marketing Automation Software Expert gives Positive review on MindMatrix's platform, AMP
3. New Organization Plans to Use Independent Peer Review to Put Millions of Hours Back into Research
4. BioNeutral Group Receives Positive Testing Results From A Global Independent Laboratory For Its Ygiene Sterilant Against Anthrax Spores
5. No on Prop. 37: French Rat Study Author Made Reporters Sign Confidentiality Agreements Prohibiting them from Consulting Independent Scientific Experts
6. China Integrated Energy Inc. Completes Independent Investigation
7. Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman
8. The Blood Sugar-Cardiac-Cancer Connection
9. Breakthrough Book From GLS Sciences Ends Blood Sugar Abuse in Time For The Holidays
10. Autoimmune disease retraining white blood cells
11. The Leading Edge Of Medical Innovation: New Prenatal Genetic Tests Use Moms Blood To Learn About Her Baby
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... -- Spherix Incorporated (Nasdaq: SPEX ) -- an intellectual property development ... property, today provided an update on the Company,s cases ... Texas and announcing that those ... Re-examination ("IPR") proceedings that VTech and Uniden filed ... on only certain claims of two of the patents ...
(Date:2/3/2016)... Feb. 3, 2016   ViaCyte, Inc ., ... first pluripotent stem cell-derived islet replacement therapy for ... development, today announced that ViaCyte and Janssen Biotech, ... Johnson & Johnson, have agreed to consolidate the ... The agreement provides ViaCyte with an exclusive license ...
(Date:2/3/2016)... , Feb. 3, 2016 New ... more than $1 million for researchers in ... on health-related research that demonstrates exciting potential.   ... of funding for the New Jersey Health Foundation Research ... members at these educational institutions— Princeton University, Rutgers ...
(Date:2/3/2016)... -- Silk Therapeutics, Inc., today announced the closing of a $6 ... a total of $10.25 million in Series A funding based ... round was led by existing investor The Kraft Group of ... investors Lear Corporation and Highland Consumer Partners, as well as ... Richard Sackler , MD, with Summer Road, LLC; Erin ...
Breaking Biology Technology:
(Date:2/3/2016)... , February 4, 2016 --> ... to SEK 1,351.5 M (105.0), up 1,187% compared with fourth quarter of ... amounted to SEK 517.6 M (loss: 30.0). Earnings per share ... activities was SEK 537.4 M (neg: 74.7). , ... , Revenues amounted to SEK 2,900.5 M (233.6), up 1,142% compared with ...
(Date:2/2/2016)... YORK , Feb. 2, 2016 /PRNewswire/ ... facilities are primarily focused on medical screening ... measure point-of-care parameters. Wearable devices that facilitate ... user,s freedom of movement are being bolstered ... for human biomedical signal acquisition coupled with ...
(Date:2/2/2016)... 2016   Parabon NanoLabs (Parabon) announced ... Research Office and the Defense Forensics and Biometrics ... the company,s Snapshot Kinship Inference software ... generally, defense-related DNA forensics.  Although Snapshot is best ... and ancestry from DNA evidence), it also has ...
Breaking Biology News(10 mins):